Struggling Bay Area biotech firm, once worth $1B, lays off almost entire staffKronos Bio is undergoing major layoffs and has discontinued its only clinical drug due to adverse effects.
Martin Lazaro, oncologist: With immunotherapy, we are seeing long-term survivors from unthinkable tumors'Cancer treatment is becoming increasingly personalized based on molecular alterations in tumors.Patients are now actively involved in decision-making about their treatment plans.